For the year ending 2025-12-31, HBIO had $4,506K increase in cash & cash equivalents over the period. $5,471K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -56,700 |
| Depreciation | 1,743 |
| Amortization of intangible assets | 4,202 |
| Goodwill impairment - note 5 | 47,951 |
| Amortization of deferred financing costs | 1,322 |
| Stock-based compensation | 1,855 |
| Deferred income taxes and other | 680 |
| Loss on pension settlement - note 8 | 1,233 |
| Loss on extinguishment of debt | -130 |
| Loss on equity securities - note 12 | 0 |
| Accounts receivable | 934 |
| Inventories | -2,947 |
| Other assets | -1,521 |
| Accounts payable and other liabilities | 2,300 |
| Contract liabilities | -161 |
| Net cash provided by operating activities | 6,729 |
| Additions to property, plant and equipment | 1,258 |
| Capitalized software development costs | 605 |
| Proceeds from sale of marketable equity securities | 0 |
| Net cash used in investing activities | -1,863 |
| Borrowing from revolving line of credit | 0 |
| Borrowing from term loans | 40,000 |
| Repayment of revolving line of credit | 12,650 |
| Repayment of term debt | 24,700 |
| Payment of debt issuance costs | 3,832 |
| Proceeds from exercise of stock options and employee stock purchase plan | 47 |
| Taxes paid related to net share settlement of equity awards | 156 |
| Net cash used in financing activities | -1,291 |
| Effect of exchange rate changes on cash | 931 |
| Increase (decrease) in cash and cash equivalents | 4,506 |
| Cash and cash equivalents at beginning of period | 4,108 |
| Cash and cash equivalents at end of period | 8,614 |
HARVARD BIOSCIENCE INC (HBIO)
HARVARD BIOSCIENCE INC (HBIO)